Wells Fargo Maintains Equal-Weight on Bicara Therapeutics, Raises Price Target to $16
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Eva Fortea Verdejo maintains Bicara Therapeutics (NASDAQ:BCAX) with a Equal-Weight and raises the price target from $11 to $16.
Wells Fargo analyst Eva Fortea Verdejo maintains Bicara Therapeutics (NASDAQ:BCAX) with a Equal-Weight and raises the price target from $11 to $16.